Alnylam Pharmaceuticals | search
Click here to view Alnylam Pharmaceuticals news from 60+ newspapers.
Bookmark or Share- Alnylam Pharmaceuticals Inc (ALNY) (Q1 2024) Earnings Call Transcript ...Alnylam Pharmaceuticals Inc ( NASDAQ:ALNY) reported a robust 32% year-over-year growth in product revenue, reaching $365 million in Q1 2024. The TTR franchise of Alnylam Pharmaceuticals Inc ...
- Alnylam® PharmaceuticalsLearn about Alnylam Pharmaceuticals, RNAi therapeutics, and the company's efforts in treating amyloidosis, hyperoxaluria, and porphyria.
- Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2023 ...About Alnylam Pharmaceuticals. Alnylam Pharmaceuticals (Nasdaq: ALNY) has led the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to...
- Alnylam Pharmaceuticals - WikipediaAlnylam Pharmaceuticals, Inc. is an American biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.
- Investor Relations | Alnylam Pharmaceuticals, Inc.The Investor Relations website contains information about Alnylam Pharmaceuticals, Inc.'s business for stockholders, potential investors, and financial analysts.
More
